Glucocorticoids induce apoptosis in chronic lymphocytic leukemia (CLL) cells through a caspase-dependent mechanism. However, their mechanism of action remains unknown. We have studied the regulation of the proapoptotic BH3-only Bcl-2 interacting mediator of cell death (BIM) in CLL cells. We demonstrate that glucocorticoids upregulate BIM at protein and mRNA levels. We have investigated the ability of different survival signals, such as 12-O-tetradecanoylphorbol 13-acetate (TPA), stromal cell-derived factor-1a (SDF-1a), interleukin 4 (IL-4) and B-cell receptor (BCR) activation, to influence the levels of BIM and its induction by glucocorticoids. TPA downregulates BIM EL by extracellular signal-regulated kinase (ERK)-mediated BIM phosphorylation and further proteasomemediated degradation. However, SDF-1a and BCR activation induce transient BIM phosphorylation, without protein degradation. Proteasome inhibitors do not modify the levels of BIM with respect to untreated cells. However, they induce apoptosis and inhibit TPA-induced BIM EL degradation, leading to its accumulation. In conclusion, the results implicate BIM in glucocorticoid-induced apoptosis in CLL cells. BIM EL phosphorylation through the ERK pathway targets the protein for proteasomal degradation.
Introduction
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in human adults in Western countries. It is a heterogeneous disease, characterized by the accumulation of long-lived CD5 þ B lymphocytes in peripheral blood and bone marrow. 1 Clinically used chemotherapeutic agents act by inducing apoptosis in CLL lymphocytes. Glucocorticoids are potent inducers of apoptosis in CLL cells, through a caspase-dependent mechanism. [2] [3] [4] Furthermore, the inhibition of either protein kinase C (PKC) or the phosphatidylinositol 3-kinase (PI3K)/Akt pathways increases glucocorticoid-induced apoptosis in the presence of survival factors. 5 However, the mechanism of glucocorticoidinduced apoptosis in CLL remains largely unknown.
Bcl-2 family proteins are critical regulators of apoptosis in CLL cells. High levels of Bcl-2 have been well documented in CLL cells. [6] [7] [8] Furthermore, CLL cells express other anti-apoptotic Bcl-2 family members, such as Mcl-1, Bcl-X L , Bcl-W L and Bfl-1. Such proteins have been implicated in the survival of these cells. [8] [9] [10] [11] Activation of the multidomain proapoptotic proteins Bax and Bak mediate the release of cytochrome c from mitochondria and activation of caspases through the mitochondrial pathway in CLL cells. 12 However, most apoptotic stimuli, including glucocorticoids, do not alter Bax or Bak protein levels. Activation of Bax or Bak is mediated by regulation of the BH3-only members of the family through transcriptional or post-transcriptional mechanisms. Thus, Puma is a transcriptional target when the p53 pathway is activated in CLL by irradiation or drugs such as fludarabine or MDM2 inhibitors. 13, 14 CLL cells also express the BH3-only proteins Bid, Bmf, Noxa and Bcl-2 interacting mediator of cell death (BIM); however, the control of these proteins has been poorly investigated in CLL cells. 11, [13] [14] [15] BIM is a Bcl-2 family member, which belongs to the BH3-only proteins. BIM was discovered in a lymphoma cell line, by its ability to interact with Bcl-2 and to induce apoptosis. 16 Very recently, BIM has been shown to interact with all the prosurvival members of the Bcl-2 family. 17 Of all BH3-only proteins examined, only BIM and Bid have the capacity to act as direct activators of Bax and Bak. 18 Different isoforms have been described for BIM. 19 However, there are three major, abundant, splice variants, all of which are proapoptotic. They are usually described as short, long and extra long (BIM S , BIM L and BIM EL , respectively). By gene target deletion experiments, BIM was implicated in several apoptotic stimuli, such as cytokine deprivation, calcium ion flux and microtubule perturbation. Moreover, BIM À/À T-lymphocytes were partially resistant to glucocorticoid-induced apoptosis. 20 Mice lacking BIM have defects in deletion of autoreactive B and T cells, [21] [22] [23] and loss of BIM confers protection at the mitochondrial membrane in a BAK-or BAX-dependent manner. 24 Recent studies using microarray approaches have demonstrated that glucocorticoids induce BIM in murine and human leukemia cell lines. [25] [26] [27] In addition, RNAi experiments in precursor B-cell (pre-B) acute lymphoblastic leukemia (ALL) cell lines have demonstrated the role of BIM in apoptosis induced by glucocorticoids. 28 Some reports offer evidence that the induction of BIM by glucocorticoids is essential to the complete apoptotic response in acute lymphoblastic leukaemia cell lines and xenografts. 28, 29 Deletions of the BIM gene have been identified in mantle cell lymphoma samples and cell lines. 30 We have studied the regulation of BIM levels in CLL cells in this paper. We also analysed the modulation of BIM by glucocorticoids and by several survival signals, such as 12-Otetradecanoylphorbol 13-acetate (TPA), stromal cell-derived factor-1a (SDF-1a), interleukin 4 (IL-4) and B-cell receptor (BCR) activation. We demonstrate that glucocorticoids induce BIM at protein and mRNA levels. In addition, we show that TPA downregulates BIM and overrides glucocorticoid induction through extracellular signal-regulated kinase (ERK)-mediated BIM phosphorylation and further proteasomal degradation. 
Materials and methods

Patients with CLL and cell isolation
Cell culture
CLL lymphocytes were cultured immediately after thawing, at a concentration of 2-5 Â 10 6 cells/ml in RPMI 1640 culture medium (Biological Industries, Beit Haemek, Israel). The medium was supplemented with 10% heat-inactivated fetal bovine serum (GIBCO-BRL, Paisley, UK), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (Biological Industries, Beit Haemek, Israel). Cells were incubated at 371C in a humidified atmosphere at 5% carbon dioxide. The viability of CLL cells was measured before incubation with drugs. Factors were added 2 h after the beginning of the culture and cells were incubated for the indicated periods of time.
Cytokines and chemical reagents
TPA, dimethyl sulfoxide (DMSO), MG132 (Z-Leu-Leu-Leu-al), dexamethasone, doxorubicin, chlorambucil and fludarabine were obtained from Sigma-Aldrich (Steinheim, Germany). Bisindolylmaleimide I (BisI), U0126 and LY294002 were all purchased from Calbiochem-Novabiochem (San Diego, CA, USA). Annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) were from Bender MedSystems (Vienna, Austria). Recombinant human IL-4 and SDF-1a were purchased from Immunotools (Friesoythe, Germany). Goat F(ab 0 ) 2 antihuman immunoglobin (Ig) M and goat IgG were purchased from Southern Biotechnology Associates (Birmingham, AL, USA).
Analysis of apoptosis by flow cytometry
Cell viability was determined by measuring phosphatidylserine exposure and membrane integrity. This was determined by Annexin V-FITC and PI double staining, and a flow cytometric analysis using the FACSCalibur and the CellQuest software, as described elsewhere. 31 Cell viability was measured as the percentage of Annexin V and PI double-negative cell population.
Western blot analysis
Cell were lysed with Laemmli sample buffer, and Western blot analysis was performed as described previously 5 (see Supplementary Information for detailed method). The membranes were incubated with polyclonal antibodies against BIM (BD PharMingen, Erembodegem, Belgium), Mcl-1 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and phosphorylated Akt (Ser-473) (Cell Signaling Technologies, Beverly, MA, USA) and monoclonal antibodies against Bcl-2 (Dako, A/S, Glostrup, Denmark) and phosphorylated ERK-1/2 (Thr-202/Tyr-204) (Cell Signaling Technologies, Beverly, MA, USA). Polyclonal antibody against ERK-1/2 (antiserum E1B) 32 was a kind gift of Dr Francesc Viñ als. Antibody binding was detected using a secondary antibody and the enhanced chemiluminescence (ECL) detection kit (Amersham, Bucks, UK).
Quantitative real-time PCR
Quantitative real-time polymerase chain reaction (PCR) was performed as described previously 14 (see Supplementary Information for detailed method).
RT-MLPA
RNA was analysed by reverse transcriptase multiplex ligationdependent probe amplification (RT-MLPA), using SALSA MLPA KIT R011 Apoptosis mRNA from MRC-Holland (Amsterdam, The Netherlands), 33 as described previously 14 (see Supplementary Information for detailed method).
Statistical analysis
Data were analysed using SPSS 11.0 software package (Chicago, IL, USA). Results are shown as mean7s.e.m. of values obtained in independent experiments. The paired Student's t-test was used to compare the differences between paired samples.
Results
Glucocorticoids induce BIM expression in CLL
To study the role of BIM in the apoptosis of CLL cells, we first examined the basal levels of the major BIM isoforms BIM EL , BIM L and BIM S in CLL samples ( Figure 1a ). All the patient samples analysed had detectable basal levels of BIM EL and of a band compatible with BIM L or BIM molecular weight.
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Levels were variable among patient samples. In contrast, the BIM S isoform was only detected in some patients when the Western blots were overexposed. As a loading control, we measured Bcl-2 and ERK levels in the patient samples.
As BIM has been implicated in the apoptotic response to multiple stimuli, we analysed different apoptotic inducers in CLL cells. These included dexamethasone, the PI3K inhibitor LY294002, doxorubicin, fludarabine and chlorambucil. Western blot analysis of cells from two patients treated with these drugs for 48 h showed that only glucocorticoids induced BIM EL and BIM L/ , although all the drugs tested induced loss of viability (Figure 1b) . The induction of BIM levels was higher for the BIM EL isoforms than for the BIM L/ bands. However, BIM L/ induction was manifested in most of the patient samples analysed. BIM levels also increased during spontaneous apoptosis (compare control point at 0 with 48 h). Next, we analysed some of the Western blots by densitometry, to quantify the induction of BIM EL . The ratio BIM EL /Bcl-2 was calculated for spontaneous (ct) and dexamethasone (D)-induced apoptosis at 24 or 48 h, with respect to untreated cells at time 0 (Figure 1c) . The increase in BIM EL by glucocorticoids, with respect to the control at time 0, was 471.3 times for 24 h and 5.971.0 times for 48 h. The increase due to spontaneous apoptosis was 2.170.4 times for 24 h and 3.170.5 times for 48 h. Thus, BIM is induced in CLL cells during spontaneous and glucocorticoid-induced apoptosis.
To further investigate the effect of glucocorticoids on BIM in CLL cells, we performed immunoblot and quantitative real-time PCR analysis on BIM induction in time-course experiments. Western blot analysis revealed time-dependent induction of the BIM EL protein by dexamethasone. This was perceptible at 12 h and higher at 24 and 48 h (Figure 2a) . As a control, Bcl-2 and ERK protein levels were not affected by dexamethasone. We analysed BIM mRNA levels by quantitative real-time PCR analysis to assess whether glucocorticoids induce transcription of the BIM gene. BIM mRNA levels did not increase during spontaneous apoptosis (data not shown). Dexamethasone treatment strongly increased BIM mRNA levels at 12, 24 and 48 h (270.6, 671.4 and 2.670.9 times, compared to the control cells at the same time, respectively) ( Figure 2b) .
To investigate the specificity of BIM induction by glucocorticoids in CLL samples, we analysed the mRNA expression of the Bcl-2 family members and other genes involved in the control of apoptosis by performing RT-MLPA.
14,33,35 BIM was significantly (Po0.001) induced by glucocorticoids (Figure 2c ) and this induction was not affected by the pan-caspase inhibitor Z-VAD.fmk (data not shown). Importantly, none of the other proapoptotic genes were significantly induced by glucocorticoids. A smaller increase was also observed in the anti-apoptotic gene FLIP (Po0.005). The levels of MCL-1 mRNA were significantly lower in glucocorticoid-treated cells (Po0.001), and this effect was partially inhibited by the pan-caspase inhibitor Z-VAD.fmk (data not shown). Interestingly, one of the patients analysed in the MLPA experiments had mutations in the TP53 gene. In this patient, dexamethasone-induced apoptosis and BIM induction (2.5-fold induction compared to the untreated cells) were not significantly different from wild-type p53 samples. Thus, RT-MLPA analysis revealed that BIM is the only proapoptotic gene significantly induced by glucocorticoids.
Effect of survival factors on the induction of BIM by glucocorticoids
We assessed the effect of two well-known survival factors for CLL cells, phorbol esters (TPA) 5 and SDF-1a, 36 on the induction of BIM. The incubation of cells with TPA for 48 h, at doses that protect CLL cells from apoptosis, eliminated BIM EL (Figure 3a) . Interestingly, TPA overrode and completely reverted the induction of BIM EL and the decrease in cell viability produced by dexamethasone. In contrast, a glucocorticoid-dependent increase in BIM L/ was not downregulated by TPA. However, TPA produced a shift in the mobility of BIM L/ . SDF-1a did not modify the levels of BIM EL or BIM L/ . In addition, it did not revert the induction of BIM by glucocorticoids, or modify the loss of viability induced by glucocorticoids (Figure 3a) .
Next, we further examined the role of survival factors in early BIM regulation. Treatment of CLL cells for 5 and 30 min with TPA or with SDF-1a produced a shift in the mobility of BIM EL and BIM L/ (Figure 3b) . Several diffuse bands with less electrophoretic mobility appeared, substituting the band that corresponded to the control samples. These have been described as different phosphorylated forms of the BIM EL isoform. 34 In addition, TPA and SDF-1a induced a decrease in BIM EL protein. TPA and SDF-1a activated ERK and Akt pathways (Figure 3b, middle panels) . However, SDF-1a induced ERK activation after 5 min incubation but did not sustain it after 30 min incubation. BIM EL was phosphorylated for short periods of time (5-30 min), parallel to the activation of ERK (data not shown). In contrast IL-4, which induced Akt phosphorylation on Ser-473 but did not activate the ERK pathway, did not modify BIM electrophoretic mobility at any incubation time (Figure 3b and data not shown). We analysed the effect of BCR activation on BIM regulation in patients in whom BCR activation induced activation of ERK and Akt. Activation of BCR induced BIM phosphorylation in the three samples analysed (Supplementary Figure 1a) . Similar to SDF-1a, our results indicate that BCR-induced BIM phosphorylation was transitory and parallel to ERK activation, and that it disappeared at long incubation times (Supplementary Figure 1b) .
We used BisI, an inhibitor of most PKCs, and U0126, an inhibitor of ERK activation, to confirm the role of ERK in TPAinduced BIM phosphorylation. Both U0126 and BisI inhibited (Figure 3c ). These data confirmed the involvement of the ERK pathway in BIM phosphorylation in CLL cells.
Proteasome-dependent degradation of phosphorylated BIM in CLL
We studied the role of proteasome in the disappearance of BIM EL subsequent to its TPA-induced phosphorylation. Thus, CLL cells were treated with TPA alone, or in the presence of proteasome inhibitors, and BIM protein levels were analysed at different times. TPA induced BIM EL and BIM L/ phosphorylation at 1 h, and only BIM EL disappeared after 2-3 h of TPA treatment (Figure 4a ). Preincubation for 1 h with the proteasome inhibitor MG132 inhibited TPA-induced BIM EL degradation and caused its accumulation. As a control, Mcl-1, which is a short half-life protein regulated by ubiquitylation and degraded by proteasome, was accumulated after MG132 treatment. Bcl-2 and ERK were not affected by any of these treatments (Figure 4a) .
Finally, we investigated the effect of proteasome inhibitors, either alone or in combination with TPA, on cell viability and BIM protein levels at longer incubation times. Treatment of CLL cells for 24 h with MG132 alone did not modify the levels of BIM (Figure 4b ). However, it caused an accumulation of Mcl-1 and a strong decrease in cell viability (cell viability decreased from 8876 to 5575% (n ¼ 9) after incubation with 0.5 mM MG132 for 24 h) (Figure 4c) . TPA induced the degradation of BIM, and an increase in Mcl-1 levels and cell viability. Interestingly, when both drugs were combined, MG132 partially rescued BIM expression (Figure 4b) , and induced apoptosis at the same level as that in the absence of TPA (cell viability was 4775% (n ¼ 9) after incubation with 0.5 mM MG132 plus 10 nM TPA for 24 h) (Figure 4c ).
Discussion
The present study analyses, for the first time, the regulation of the proapoptotic BH3-only protein BIM in CLL cells by glucocorticoids, proteasome and several survival signals.
Our results demonstrate that BIM is implicated in the induction of apoptosis by glucocorticoids in CLL cells. In addition, we show that activation of PKC and MAPK/ERK pathways downregulate BIM through phosphorylation, which marks the protein for proteasome-mediated degradation.
Although the induction of BIM by glucocorticoids has been examined in some leukemias, 27 ,29,37-39 it has not been studied previously in CLL cells. We demonstrate that BIM mRNA and protein are induced by glucocorticoids in CLL cells. By using RT-MLPA with CLL samples, we demonstrate that BIM is the only proapoptotic gene induced by glucocorticoids. None of the other BH3-only members were induced by glucocorticoids. The increase in the anti-apoptotic gene FLIP is inconsistent with the apoptotic action of glucocorticoids. In fact, glucocorticoids induce a decrease in the levels of FLIP protein in carcinomas. 40 The effect of glucocorticoids in MCL-1 mRNA levels is caspasedependent and it is likely located downstream of the induction of BIM. This caspase-mediated downregulation of MCL-1 mRNA has been reported previously in other models. 41 Thus, BIM is the only proapoptotic Bcl-2 family member clearly involved in the apoptotic action of glucocorticoids in CLL cells. Lymphocytes and thymocytes that are deficient in BIM show resistance to glucocorticoid-induced apoptosis. 20, 27 The mechanism for the induction of BIM by glucocorticoids remains to be elucidated.
However, it could be an indirect mechanism, as the human BIM promoter does not contain a clear glucocorticoid response element. 25 CLL is considered a paradigm of a cancer with decreased apoptosis where environmental survival signals probably contribute to this resistance. In addition, BIM is thought to be involved in apoptosis following withdrawal of the survival factors. 42, 43 In several cellular models, BIM is regulated at the transcriptional level by survival signals, which act through the Akt and forkhead transcription factors. 42, 44, 45 It is also regulated at the post-transcriptional level through the ERK Figure 3 Effect of the survival factors on basal and glucocorticoidinduced BIM levels. Analysis of the signalling pathways implicated in the phosphorylation of BIM. (a) Cells from one representative CLL patient were treated with 10 mM dexamethasone (D) alone or in the presence of 10 nM TPA (T) or 50 ng/ml SDF-1a (S) for 48 h. Cells were collected and lysed for Western blot analysis, as described in Materials and methods. Total levels of BIM, Bcl-2 and ERK were analysed. Viability was measured by analysis of phosphatidylserine exposure and PI uptake. It is expressed at the top of the figure. This is a representative patient from eight that were assayed. (b) Cells from one representative CLL patient were untreated (ct) or treated for 5 or 30 min with 10 nM TPA (T), 50 ng/ml SDF-1a (S) or 10 ng/ml IL-4 (I). Cells were lysed and analysed by Western blot. Total levels of BIM, Bcl-2, ERK, phospho-ERK (P-ERK) and phospho-Akt (P-Akt, Ser-473) were analysed. The asterisk in the P-Akt pannel represents an unspecific band. This is a representative experiment of five of the patient samples analysed. (c) Cells from one representative CLL patient were treated for 1 h with 10 nM TPA (T) either alone or in the presence of 5 mM BisI or 1 mM U0126, preincubated for 1 h before TPA treatment. The samples were lysed and analysed by Western blot. Total levels of BIM, Bcl-2, ERK and P-ERK were analysed. This is a representative patient from 10 that were assayed. pathway. 42, 43, [45] [46] [47] [48] In this case, BIM is phosphorylated and degraded by proteasome. 47, 48 These antecedents prompted us to investigate the ability of some survival signals such as TPA, 3 IL-4, 5 activation of BCR 49 or the chemokine SDF-1a 36 to influence the levels of BIM in CLL cells. We show that ERK is activated by TPA, SDF-1a and BCR activation, but not by IL-4. This finding is in agreement with previous literature. 5, 36, 50 Akt was phosphorylated by all four survival signals. However, the data on IL-4 suggest that activation of Akt alone does not affect the protein levels of BIM in CLL cells. Our results demonstrate that activation of PKC and ERK blocks induction of BIM by glucocorticoids. The mechanism of this effect is probably the degradation of phosphorylated BIM by proteasome. SDF-1a, which activates ERK kinase, 36 had no effect on BIM phosphorylation or on the induction of BIM induced by glucocorticoids during long incubation times. The transitory phosphorylation of BIM by SDF-1a likely explains its inability to downregulate BIM and revert glucocorticoid BIM induction. Thus, the phosphorylation of BIM EL by SDF-1a appears to be transitory, and might be dependent on the activation of ERK.
The fact that PKC activators do not downregulate BIM L/ , but inhibitors of ERK revert its change in mobility, is intriguing. BIM L lacks the ERK kinase phosphorylation domain but BIM 1 contains it. 34 However, the BIM L/ band that we detected in CLL is not downregulated by the proteasome pathway. One possible explanation is that we detected the BIM 1 isoform, which is phosphorylated through the ERK pathway. However, unlike BIM EL , BIM 1 is not a substrate for proteasome degradation. 34 To our knowledge, there are no reports on the control of BIM by survival signals.
Finally, in our ex vivo experiments, proteasome inhibitors increase the levels of phosphorylated BIM EL isoforms in the presence of PKC activators. Thus, hypothetically, in the presence of survival signals, which induce the phosphorylation and degradation of BIM, proteasome inhibitors could induce accumulation of BIM EL in vivo. In agreement with the results obtained from other cellular systems, 48, 51, 52 BIM EL could act in CLL as a target for survival signals that activate PKC and the ERK pathway. This phosphorylation targets the protein for proteasome-mediated degradation. 47, 48 When CLL cells are incubated in the absence of survival signals, proteasome inhibitors induce apoptosis without affecting BIM levels, indicating that additional proteasome targets are involved.
In summary, BIM seems to be an important protein in apoptosis induced by glucocorticoid treatment. It emerges as a target for proteasome in CLL cells when it is specifically phosphorylated through the ERK pathway. Thus, BIM could be involved in the mechanism of action of bortezomib, which inhibits proteasome and is used in CLL treatment. 53 
